US 7,598,268 B2
	Quinolinone derivatives
Paul A. Renhowe, Danville, Calif. (US); Sabina Pecchi, Oakland, Calif. (US); Timothy D. Machajewski, Martinez, Calif. (US); Cynthia M. Shafer, El Sobrante, Calif. (US); Clarke Taylor, Albany, Calif. (US); William R. McCrea, Berkeley, Calif. (US); Christopher McBride, Oakland, Calif. (US); and Elisa Jazan, Richmond, Calif. (US)
Assigned to Novartis Vaccines & Diagnostics, Inc., Emeryville, Calif. (US)
Filed on Jul. 08, 2004, as Appl. No. 10/886,950.
Application 10/886950 is a continuation of application No. 10/284017, filed on Oct. 30, 2002, granted, now 6,774,237.
Application 10/284017 is a continuation of application No. 09/951265, filed on Sep. 11, 2001, granted, now 6,605,617.
Claims priority of provisional application 60/232159, filed on Sep. 11, 2000.
Prior Publication US 2005/0054672 A1, Mar. 10, 2005
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/44 (2006.01)

U.S. Cl. 514—312  [546/157]

5 Claims

1. A method of treating a cancer patient in need of an inhibitor of a receptor tyrosine kinase, comprising: administering an effective amount of a compound, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of the tautomer, or a pharmaceutical formulation comprising the compound, the tautomer of the compound, the pharmaceutically acceptable salt of the compound, and/or the pharmaceutically acceptable salt of the tautomer to a patient in need thereof, wherein the receptor tyrosine kinase is vascular endothelial growth factor receptor tyrosine kinase or basic fibroblast growth factor receptor and the receptor tyrosine kinase is inhibited in the patient, after administration and further wherein the compound is 4-amino-5-fluoro-3[5-4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one.